NYSEMKT: OCX
Oncocyte Corp Stock

$1.80+0.11 (+6.51%)
Updated Jan 24, 2022
OCX Price
$1.80
Fair Value Price
N/A
Market Cap
$166.02M
52 Week Low
$1.62
52 Week High
$6.57
P/E
-4.29x
P/B
1.67x
P/S
70.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.64M
Earnings
-$34.52M
Gross Margin
-30%
Operating Margin
-954.49%
Profit Margin
-743.8%
Debt to Equity
0.69
Operating Cash Flow
-$35M
Beta
1.11
Next Earnings
Mar 14, 2022
Ex-Dividend
N/A
Next Dividend
N/A

OCX Overview

Zen Score

High
Medium
Low
Industry Average (19)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OCX is good value based on its book value relative to its share price (1.67x), compared to the US Biotechnology industry average (4.59x)
Valuation
OCX's cash and short-term investments ($45.96M) cannot cover OCX's cash burn for the next year ($37.04M), once increasing cash burn (124.84%) is accounted for
Financials
OCX's profit margin has increased... subscribe to Premium to read more.
Financials
There are 16 more OCX due diligence checks available for Premium users.

OCX News

Valuation

OCX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.29x
Industry
20.6x
Market
34.17x

OCX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.67x
Industry
4.59x
OCX is good value based... subscribe to Premium to read more.
Valuation

OCX's financial health

Profit margin

Revenue
$984.0k
Net Income
-$13.8M
Profit Margin
-1,402.4%
OCX's cash and short-term investments... subscribe to Premium to read more.
Financials
OCX's profit margin has increased... subscribe to Premium to read more.
Financials

Assets to liabilities

Assets
$168.3M
Liabilities
$69.0M
Debt to equity
0.69
OCX's short-term assets ($47.59M) exceed... subscribe to Premium to read more.
Financials
OCX's long-term liabilities ($55.62M) exceed... subscribe to Premium to read more.
Financials
OCX's debt has increased relative... subscribe to Premium to read more.
Financials
OCX's debt to equity ratio... subscribe to Premium to read more.
Financials

Cash flow

Operating
-$11.0M
Investing
-$394.0k
Financing
$8.2M
OCX's cash and short-term investments... subscribe to Premium to read more.
Financials

Oncocyte Corp Stock FAQ

What is Oncocyte Corp's quote symbol?

(NYSEMKT: OCX) Oncocyte Corp trades on the NYSEMKT under the ticker symbol OCX. Oncocyte Corp stock quotes can also be displayed as NYSEMKT: OCX.

What is the 52 week high and low for Oncocyte Corp (NYSEMKT: OCX)?

(NYSEMKT: OCX) Oncocyte Corp's 52-week high was $6.57, and its 52-week low was $1.62. It is currently -72.6% from its 52-week high and 11.11% from its 52-week low.

How much is Oncocyte Corp stock worth today?

(NYSEMKT: OCX) Oncocyte Corp currently has 92,231,437 outstanding shares. With Oncocyte Corp stock trading at $1.80 per share, the total value of Oncocyte Corp stock (market capitalization) is $166.02M.

Oncocyte Corp stock was originally listed at a price of $9.00 in Jan 4, 2016. If you had invested in Oncocyte Corp stock at $9.00, your return over the last 6 years would have been -80%, for an annualized return of -23.53% (not including any dividends or dividend reinvestments).

How much is Oncocyte Corp's stock price per share?

(NYSEMKT: OCX) Oncocyte Corp stock price per share is $1.80 today (as of Jan 24, 2022).

What is Oncocyte Corp's Market Cap?

(NYSEMKT: OCX) Oncocyte Corp's market cap is $166.02M, as of Jan 25, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oncocyte Corp's market cap is calculated by multiplying OCX's current stock price of $1.80 by OCX's total outstanding shares of 92,231,437.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.